Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.54 |
| ▸ | CNR2 | P34972 | 1/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | FABP4 | P15090 | 1/20 | 0.46 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.43 |
| ▸ | CSNK2A2 | P19784 | 3/20 | 0.43 |
| ▸ | CSNK2B | P67870 | 3/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.43 |
| ▸ | FEN1 | P39748 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | GUSB | P08236 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30686840 | 1.00 | SRC (0.54) | SRCCNR2HDAC2HDAC6HDAC3 | |
| SCHEMBL26966719 | 0.86 | CSNK2A2 (0.55) | HDAC2HDAC6HDAC3FABP4CSNK2A1 | |
| SCHEMBL27175646 | 0.86 | CNR2 (0.61) | SRCCNR2HDAC2HDAC6HDAC3 | |
| SCHEMBL30686843 | 0.84 | ROCK2 (0.57) | HDAC2HDAC6HDAC3CSNK2A1CSNK2A2 | |
| SCHEMBL26966713 | 0.84 | ROCK2 (0.57) | HDAC2HDAC6HDAC3CSNK2A1CSNK2A2 | |
| SCHEMBL13011169 | 0.78 | CNR2 (0.58) | SRCCNR2HDAC2HDAC6HDAC3 | |
| SCHEMBL26966711 | 0.78 | KDM4E (0.60) | CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL28039674 | 0.78 | CYP19A1 (0.64) | SRCHDAC6HDAC3FABP4 | |
| SCHEMBL13011637 | 0.77 | CNR2 (0.56) | SRCCNR2HDAC2HDAC6HDAC3 | |
| SCHEMBL26966718 | 0.76 | ALDH1A1 (0.49) | SRCCSNK2A1CSNK2A2CSNK2BGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11851430-B1 | Pyrido[4,3-B]indole-7-carboxylic acid compounds as CK2 inhibitors | King Faisal University (SA) | 2023-12-26 | — | — | US | claimed |
| US-11851430-B1 | Pyrido[4,3-B]indole-7-carboxylic acid compounds as CK2 inhibitors | King Faisal University (SA) | 2023-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11851430-B1 | Pyrido[4,3-B]indole-7-carboxylic acid compounds as CK2 inhibitors | CSNK2A3, CSNK2A1, CSNK2A2 | SRC 404/4885CNR2 144/4885HDAC2 1495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.